Lv6
2400 积分 2025-03-26 加入
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
17小时前
已完结
C-reactive protein, pharmacological treatments and diet: how to target your inflammatory burden
17小时前
已完结
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
17小时前
待确认
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial
17小时前
已完结
Systemic Inflammation and Recurrence After Atrial Fibrillation–Related Stroke
17小时前
已完结
Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial
21小时前
已完结
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
22小时前
已完结
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
22小时前
已完结
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
22小时前
已完结
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis
1天前
已完结
皖公网安备34019202002308
